Also known as Lantus, Basaglar, and Toujeo.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
Phase 3 retatrutide and Foundayo results show large weight and A1C reductions and signals of cardiovascular benefit; Phase 2 eloraTZP and additional Mounjaro/Zepbound analyses also presented.
Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.
ACHIEVE-4: Foundayo non-inferior vs insulin glargine for MACE-4 (HR 0.84); improved A1C (-1.6 vs -1.0) and weight (-8.8% vs +1.7%) at 52 wks; 57% lower all-cause death; GI AEs; FDA filing planned.
A subscription lists every plant we track for insulin glargine, with its owners and capacity. What a subscription does →
